MedTrace Logo

Strategic Use of New Generation Antidepressants for Depression

NCT01109693 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 2011

Last updated 2016-10-03

No results posted yet for this study

Summary

The purpose of the study is to establish the optimum treatment strategy for first-line and second-line antidepressants in the acute phase treatment of major depression.

Conditions

  • Unipolar Major Depressive Episode

Interventions

DRUG

Sertraline

Sertraline 50 mg/d or 100 mg/d for 6 more weeks

DRUG

Mirtazapine

Augment with or switch to mirtazapine 15-45 mg/d

Sponsors & Collaborators

  • National Center of Neurology and Psychiatry, Japan

    collaborator OTHER

  • Kyoto University

    lead OTHER

Principal Investigators

  • Toshiaki A Furukawa, MD, PhD · Kyoto University Graduate School of Medicine / School of Public Health

  • Tatsuo Akechi, MD, PhD · Nagoya City University Graduate School of Medical Sciences

  • Norio Watanabe, MD, PhD · National Center of Neurology and Psychiatry, Japan

  • Shinji Shimodera, MD, PhD · Kochi University Medical School

  • Mitsuhiko Yamada, MD, PhD · National Center of Neurology and Psychiatry, Japan

  • Masatoshi Inagaki, MD, PhD · Okayama University Graudate School of Medicine

  • Naohiro Yonemoto, MSc · National Center of Neurology and Psychiatry, Japan

  • Kazuhira Miki, MD, PhD · Miki Mental Clinic, Yokohama, Japan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2015-09-30
Completion
2015-12-31

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01109693 on ClinicalTrials.gov